Glutamate modulators for treatment of schizophrenia

Naista Zhand, David G. Attwood, Philip D. Harvey

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Over the past two decades, accumulating evidence has implicated the role of glutamatergic dysfunction in the pathophysiology of schizophrenia. There has been growing interest in glutamatergic system as a promising target for treatment of schizophrenia spectrum illness and several medications and compounds have been investigated to date. In the present study, we aim to provide a comprehensive review of clinical studies of glutamatergic agents in treatment of schizophrenia. We further discuss the heterogeneity of the results, the overall discouraging outcomes and future directions for investigating glutamatergic medications in schizophrenia.

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalPersonalized Medicine in Psychiatry
StatePublished - Jul 1 2019
Externally publishedYes


  • Glutamate
  • NMDA
  • Psychosis
  • Schizophrenia
  • Treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Neurology
  • Clinical Psychology


Dive into the research topics of 'Glutamate modulators for treatment of schizophrenia'. Together they form a unique fingerprint.

Cite this